MTOR and breast carcinoma: Khotskaya et al. confirmed these findings by reporting a hyperactive AKT/mammalian target of rapamycin (mTOR)/ribosomal protein S6 kinase beta-1 (S6K1) axis in bone-metastatic breast cancer cells, which contributes to the invasiveness of these cells [50].